Abbott Laboratories ABT
Composite 45/100; the shares have moved about 30% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 32/100 — a moderate mark against it.
Income ranks 63/100 — a moderate point in its favour. Quality ranks 54/100 — a slight point in its favour.
Valuation ranks 32/100 — a moderate mark against it. Growth ranks 38/100 — a moderate mark against it. Momentum ranks 44/100 — a slight mark against it.
What the company does Abbott Laboratories operates four global healthcare segments: Established Pharmaceuticals, Diagnostics, Nutritionals, and Medical Devices. Its portfolio includes generic drugs, diagnostic systems, infant formula, and devices for diabetes and cardiovascular care.
Key financials Abbott’s profitability metrics include ROE 10.6%, ROA 5.3%, gross margin 56.8%, operating margin 14.7%, and net margin 11.7%. Revenue grew 5.7% year-over-year, but EPS declined -51.3%. The balance sheet shows debt/equity 0.63 and current ratio 1.38.
Stock health Momentum is mixed: +30.23% over 3 months, -2.73% over 6 months, and -13.24% over 12 months. RSI(14) is 57.70, indicating neutral technical momentum. Dividend yield is 2.3% with a 47.1% payout ratio.
Price vs fair value The stock trades at a discount of 7.00% versus the analyst mean target of 119.40. - FDA granted Abbott a diabetes device clearance (24/7 Wall St.) - Medicare coverage expansion for CGMs may benefit Abbott and Dexcom (MedTech Dive) - Recent headlines highlight competitive pressure and sector rotation (Zacks)
Looking forward Forward P/E of 20.41 and PEG of 0.26 suggest moderate earnings growth expectations. Analysts cite diabetes pipeline progress and diagnostic innovation as potential catalysts.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.